Research diagnostic criteria have been published for preclinical Alzheimer disease (AD) based on biomarkers of AD-related neurodegeneration.
1 The study of carriers of AD-causing mutations provides a unique opportunity to characterize the preclinical changes associated with predisposition to AD.